| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
QIAGEN N.V (XETRA: QIA)
QIA Technical Analysis
3
| As on 9th Jun 2023 QIA SHARE Price closed @ 42.17 and we RECOMMEND Sell for LONG-TERM with Stoploss of 44.33 & Sell for SHORT-TERM with Stoploss of 43.14 we also expect STOCK to react on Following IMPORTANT LEVELS. |
QIASHARE Price
| Open | 42.22 | Change | Price | % |
| High | 42.42 | 1 Day | -0.14 | -0.33 |
| Low | 42.06 | 1 Week | -0.04 | -0.09 |
| Close | 42.17 | 1 Month | 2.24 | 5.61 |
| Volume | 416455 | 1 Year | -3.62 | -7.91 |
| 52 Week High 48.95 | 52 Week Low 38.76 | ||||
XETRA Germany Most Active Stocks
| LHAR | 2.05 | -20.23% |
| BBVA | 5.00 | -2.72% |
| BBVA | 5.00 | -2.72% |
| BBVA | 5.00 | -2.72% |
| BVBA | 0.02 | -60.00% |
| SNH | 0.16 | 6.67% |
| SNH | 0.16 | 6.67% |
| SNH | 0.16 | 6.67% |
| AT1 | 1.15 | 5.50% |
| AT1 | 1.15 | 5.50% |
XETRA Germany Top Gainers Stocks
XETRA Germany Top Losers Stocks
| QIA Daily Charts |
QIA Intraday Charts |
Whats New @ Bazaartrend |
QIA Free Analysis |
|
|
QIA Important Levels Intraday
| RESISTANCE | 42.86 |
| RESISTANCE | 42.64 |
| RESISTANCE | 42.50 |
| RESISTANCE | 42.37 |
| SUPPORT | 41.97 |
| SUPPORT | 41.84 |
| SUPPORT | 41.70 |
| SUPPORT | 41.48 |
QIA Forecast April 2024
| 4th UP Forecast | 50.15 |
| 3rd UP Forecast | 47.59 |
| 2nd UP Forecast | 46.01 |
| 1st UP Forecast | 44.43 |
| 1st DOWN Forecast | 39.91 |
| 2nd DOWN Forecast | 38.33 |
| 3rd DOWN Forecast | 36.75 |
| 4th DOWN Forecast | 34.19 |
QIA Weekly Forecast
| 4th UP Forecast | 48.72 |
| 3rd UP Forecast | 46.62 |
| 2nd UP Forecast | 45.32 |
| 1st UP Forecast | 44.02 |
| 1st DOWN Forecast | 40.32 |
| 2nd DOWN Forecast | 39.02 |
| 3rd DOWN Forecast | 37.72 |
| 4th DOWN Forecast | 35.62 |
QIA Forecast2024
| 4th UP Forecast | 64.18 |
| 3rd UP Forecast | 57.12 |
| 2nd UP Forecast | 52.76 |
| 1st UP Forecast | 48.39 |
| 1st DOWN Forecast | 35.95 |
| 2nd DOWN Forecast | 31.58 |
| 3rd DOWN Forecast | 27.22 |
| 4th DOWN Forecast | 20.16 |
QIAGEN N.V ( XETRA Germany Symbol : QIA )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
QIA Business Profile
QIAGEN N.V. provides sample to insight solutions that transform biological materials into molecular insights worldwide. The company offers primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories. It also provides interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; assays for analysis of genomic variants; and assays for prenatal testing and detection of sexually transmitted diseases and HPV; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. The company offers PCR consumables, such as quantitative PCR, reverse transcription and combinations kits for analysis of gene expression, genotyping and gene regulation instruments and technologies; human ID and forensics assay consumables, including STR assays for human ID, and assays for food contamination; PCR instruments consist of digital PCR solutions; and developed and configured OEM consumables. It offers predefined and custom NGS gene panels, library prep kits and components, whole genome amplification, etc.; bioinformatics solutions; and custom laboratory and genomic services. It serves molecular diagnostics, academia, pharmaceutical, and applied testing customers. The company has collaboration agreements with Amgen Inc.; CLIA-certified laboratories; NuProbe Global; and Personal Genome Diagnostics Inc., as well as a strategic alliance agreement with Sysmex Corporation. The company was founded in 1986 and is headquartered in Venlo, the Netherlands. Address: Hulsterweg 82, Venlo, Netherlands, 5912 PL
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service